India's first indigenous vaccine against COVID-19, Covaxin, is safe and generates immune response without any serious side effects, according to the interim results of the phase 2 trials published in The Lancet Infectious Diseases journal.
Reacting to reports that the state may run out of vaccines, the union government clarified on Tuesday that there is no shortage of Covid-19 vaccines in Rajasthan.
Coronavirus vaccination drive: The next phase of COVID-19 vaccination commenced from March for those above 60 years of age and for people aged 45 and above with specified comorbid conditions.
Delhi Chief Minister Arvind Kejriwal on Thursday received the first dose of the Covid-19 vaccine at LNJP hospital.
India's indigenously developed vaccine against coronavirus COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR, informed vaccine maker Bharat Biotech.
India's indigenously developed vaccine against coronavirus COVAXIN has demonstrated an interim vaccine efficacy of 81 per cent in its Phase 3 clinical trial. The trials involved 25,800 subjects, the largest ever conducted in India, in partnership with ICMR, informed vaccine maker Bharat Biotech.
Vaccines are being provided free of charge at the government health facilities and on a payment basis in the private health facilities. All private hospitals can charge Rs 150 for vaccines and Rs 100 for service charges fixed by the central government.
Why Congress linked Modi’s vaccination with Assam, Kerala, Puducherry polls. Opposition questions why Modi opted to take Covaxin jab. Watch this and more on Aaj Ki Baat with Rajat Sharma.
Prime Minister Narendra Modi took his first dose of the COVAXIN (Bharat Biotech) at Delhi's AIIMS on March 01 as the second phase of vaccination drive began in India today.
Covishield and Covaxin are two anti-coronavirus vaccines approved by the DGCI for emergency use in India. PM Modi received a Covaxin jab.
The government will begin the next phase of the COVID-19 vaccination drive from Monday, March 1. Citizens above 60 years and those aged 45 and above with comorbidities will be able to register and book an appointment on the Co-WIN2.0 portal from 9 am onward on Monday.
The government is upgrading the CoWIN which was being used in the initial two phases of the vaccination for immunisation of healthcare and frontline workers.
The NITI Aayog has promulgated a price range of Rs 300-500 for two Covid vaccines that would be available for the priority group at private facilities in the third phase of vaccination set to begin from March 1, sources privy to the development told IANS, adding that the Bharat Biotech's Covaxin would cost a bit higher.
"The vaccine is formulated with Algel-IMDG, which contains chemisorbed TLR7/8 agonist onto aluminum hydroxide gel to generate the requisite type of immune responses," the CSIR said in a statement.
So far Brazil has vaccinated less than 4 per cent of its population of 210 million people, with some cities stopping immunization campaigns last week due to shortages.
India is one of the world's biggest drugmakers, and an increasing number of countries have already approached it for procuring anti-coronavirus vaccines.
India launched the world's largest vaccination drive on January 16 for the healthcare and frontline workers. According to government data, over 11 lakh people have been administered two doses of Covid vaccines so far.
Makers of Covaxin, Bharat Biotech has said that they can modify the vaccine against coronavirus South African variant within 15 days. Bharat Biotech's developed India's own vaccine Covaxin against Covid-19 and was rolled out on January 16.
India has approved two vaccines -- Covaxin developed by Bharat Biotech and Covishield from the Oxford/AstraZeneca stable being manufactured by the Serum Institute of India -- for emergency use in the country.
Mathematical calculations indicate that Covaxin may provide immunity against Covid-19 for 9 to 12 months, and there may be a booster shot after this period elapses, Y.K. Gupta, the President of AIIMS Bhopal and Jammu, told IANS.
Top News
Latest News
